Biogen (BIIB) Revenue (2009 - 2026)

Biogen's Revenue history runs 18 years deep, the most recent figure standing at $2.5 billion for Q1 2026.

• In Q1 2026, Revenue rose 1.93% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $9.9 billion (up 1.23% YoY), while the FY2025 annual figure was $9.9 billion, up 2.22% from the prior year.
• Revenue was $2.5 billion for Q1 2026 at Biogen, up from $2.3 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $2.6 billion in Q2 2025 to a low of $2.3 billion in Q4 2025.
• Historically, Revenue has averaged $2.5 billion across 5 years, with a median of $2.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Revenue slipped 9.73% in 2022, then grew 7.33% in 2025.
• A 5-year view of Revenue shows it stood at $2.5 billion in 2022, then fell by 6.2% to $2.4 billion in 2023, then gained by 2.87% to $2.5 billion in 2024, then decreased by 7.14% to $2.3 billion in 2025, then rose by 8.7% to $2.5 billion in 2026.
• The last three Revenue figures came in at $2.5 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.5 billion (Q3 2025), per Business Quant data.